Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC

Journal of Virology

Volumn 86, Issue 10, 2012, Pages 5497-5507

  Zuo, Tao ^a   Liu, Donglai ^a   Lv, Wei ^b   Wang, Xiaodan ^a   Wang, Jiawen ^a   Lv, Mingyu ^a   Huang, Wenlin ^b   Wu, Jiaxin ^a   Zhang, Haihong ^a   Jin, Hongwei ^b   Zhang, Liangren ^b   Kong, Wei ^a   Yu, Xianghui ^a  

^a JILIN UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ELONGIN C; UNCLASSIFIED DRUG; VEC 5; VIF PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS; VIRION; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; CYTIDINE DEAMINASE; DRUG EVALUATION, PRECLINICAL; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84861313225     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06957-11     Document Type: Article

References (73)

1. Abdiche Y, Malashock D, Pinkerton A, Pons J. 2008. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal. Biochem. 377:209 -217.
2. Adamson CS, Freed EO. 2010. Novel approaches to inhibiting HIV-1 replication. Antiviral Res. 85:119 -141.
3. Auclair JR, et al. 2007. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins 69:270 -284.
4. Barraud P, Paillart JC, Marquet R, Tisne C. 2008. Advances in the structural understanding of Vif proteins. Curr. HIV Res. 6:91-99.
5. Bergeron JR, et al. 2010. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog. 6:e1000925.
6. Bieniasz PD. 2004. Intrinsic immunity: a frontline defense against viral attack. Nat. Immunol. 5:1109 -1115.
7. Bishop KN, et al. 2004. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14:1392-1396.
8. Blair WS, et al. 2010. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS pathogens 6:e1001220.
9. Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR. 2006. APOBEC3A and APOBEC3B are potent inhibitors of LTRretrotransposon function in human cells. Nucleic Acids Res. 34:89 -95.
10. Cen S, et al. 2010. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem. 285:16546- 16552.
11. Conticello SG, Harris RS, Neuberger MS. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009 -2013.
12. Dang Y, et al. 2008. Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J. Biol. Chem. 283:11606 -11614.
13. Dang Y, Siew LM, Zheng YH. 2008. APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated. J. Biol. Chem. 283:13124 -13131.
14. Dang Y, Wang X, Esselman WJ, Zheng YH. 2006. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80:10522-10533.
15. Ejima T, Hirota M, Mizukami T, Otsuka M, Fujita M. 2011. An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G. Int. J. Mol. Med. 28:613- 616.
16. Fujita M, et al. 2004. Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect. 6:791-798.
17. Gabuzda DH, et al. 1992. Role of vif in replication of human immunodeficiency virus type 1 in CD4_ T lymphocytes. J. Virol. 66:6489-6495.
18. Goncalves J, et al. 2002. Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J. Biol. Chem. 277:32036 -32045.
19. Greene WC, et al. 2008. Novel targets for HIV therapy. Antiviral Res. 80:251-265.
20. Harris RS, et al. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803- 809.
21. Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R. 2009. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol. Mol. Biol. Rev. 73:211- 232.
22. Holmes RK, Malim MH, Bishop KN. 2007. APOBEC-mediated viral restriction: not simply editing? Trends Biochem. Sci. 32:118 -128.
23. Hultquist JF, Harris RS. 2009. Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol. 4:605.
24. Kao S, et al. 2003. Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J. Virol. 77:1131-1140.
25. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T. 2005. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J. Biol. Chem. 280: 18573-18578.
26. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112.
27. Lee YM, Tang XB, Cimakasky LM, Hildreth JE, Yu XF. 1997. Mutations in the matrix protein of human immunodeficiency virus type 1 inhibit surface expression and virion incorporation of viral envelope glycoproteins in CD4_ T lymphocytes. J. Virol. 71:1443-1452.
28. Li J, Schantz A, Schwegler M, Shankar G. 2011. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet® biolayer interferometry. J. Pharm. Biomed. Anal. 54: 286-294.
29. Liddament MT, Brown WL, Schumacher AJ, Harris RS. 2004. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14:1385-1391.
30. Lindahl E, Hess B, van der Spoel D. 2001. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J. Mol. Model. 7:306 -317.
31. Liu B, Sarkis PT, Luo K, Yu Y, Yu XF. 2005. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol. 79:9579 -9587.
32. Liu B, Yu X, Luo K, Yu Y, Yu XF. 2004. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J. Virol. 78:2072-2081.
33. Luo K, et al. 2007. Adenovirus E4orf6 assembles with Cullin5-ElonginBElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53. FASEB J. 21:1742-1750.
34. Luo K, et al. 2005. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U. S. A. 102:11444 -11449.
35. Lv M, et al. 2011. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity. PLoS One 6:e20890.
36. Lv W, et al. 2007. Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. Org. Biomol. Chem. 5:617- 626.
37. Madani N, Kabat D. 1998. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72:10251-10255.
38. Malim MH. 2009. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 364:675- 687.
39. Mangeat B, et al. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99 -103.
40. Mariani R, et al. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
41. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398 -1403.
42. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. 2004. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18:2861-2866.
43. Mehle A, et al. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279:7792-7798.
44. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. 2006. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281:17259 -17265.
45. Miller JH, Presnyak V, Smith HC. 2007. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 4:81.
46. Nathans R, et al. 2008. Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 26:1187-1192.
47. Oberste MS, Gonda MA. 1992. Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes 6:95-102.
48. Russell RA, Pathak VK. 2007. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81:8201- 8210.
49. Schrofelbauer B, Senger T, Manning G, Landau NR. 2006. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 80: 5984-5991.
50. Schuttelkopf AW, van Aalten DM. 2004. PRODRG: a tool for highthroughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60:1355-1363.
51. Shao Q, Wang Y, Hildreth JE, Liu B. 2010. Polyubiquitination of APOBEC3G is essential for its degradation by HIV-1 Vif. J. Virol. 84: 4840-4844.
52. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404 -1407.
53. Simon JH, et al. 1998. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. EMBO J. 17:1259 -1267.
54. Simon V, et al. 2005. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS pathogens. 1:e6.
55. Stanley BJ, et al. 2008. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J. Virol. 82:8656-8663.
56. Stopak K, de Noronha C, Yonemoto W, Greene WC. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591- 601.
57. Tan S. 2001. A modular polycistronic expression system for overexpressing protein complexes in Escherichia coli. Protein Expr. Purif. 21:224 -234.
58. Tian C, et al. 2006. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80:3112-3115.
59. Vodicka MA, et al. 1997. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233: 193-198.
60. von Schwedler U, Song J, Aiken C, Trono D. 1993. Vif is crucial for human immunodeficiency virus type 1 proviralDNAsynthesis in infected cells. J. Virol. 67:4945- 4955.
61. Wang J, et al. 2011. Identification of a Cullin5-ElonginB-ElonginC E3 complex in degradation of feline immunodeficiency virus Vif-mediated feline APOBEC3 proteins. J. Virol. 85:12482-12491.
62. Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu XF. 2007. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21:217-222.
63. Xiao Z, et al. 2006. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349:290 -299.
64. Xiao Z, et al. 2007. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J. Mol. Biol. 373:541-550.
65. Yang B, et al. 2003. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J. Biol. Chem. 278:6596-6602.
66. Yang S, Sun Y, Zhang H. 2001. The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J. Biol. Chem. 276:4889-4893.
67. Yu X, et al. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056 -1060.
68. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. 2004. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18:2867-2872.
69. Zhang H, et al. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94 -98.
70. Zhang L, et al. 2008. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology 370:113- 121.
71. Zhang W, Chen G, Niewiadomska AM, Xu R, Yu XF. 2008. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One 3:e3963.
72. Zhang W, et al. 2008. Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases. Cell Microbiol. 10:1662-1675.
73. Zheng Y-H, et al. 2004. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78: 6073-6076.